Phaseline

Companies › GE Healthcare

GE Healthcare: clinical trials, targets and expected readouts

6 active drug programs in 8 registered trials: 4 Phase 2, 3 Phase 4, 1 Phase 1; Oncology, Other, Cardiovascular, Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
18F Fluoroestradiol (ESTROTEP)
Estrogen receptor imaging agent
ESR1Phase 4Metastatic Breast Cancer–
Sonazoid™
Ultrasound contrast agent
–Phase 4Focal Liver Lesions–
GE-287
Amyloid PET imaging agent (F-18 labeled)
–Phase 2Cognitive DysfunctionFeb 2027
Mangaciclanol (GEH200486 Injection)
Magnetic resonance imaging contrast agent
–Phase 2Known or Highly Suspected Central Nervous System (CNS) LesionNov 2027
GEH300079 (68Ga) Injection
68Ga-labeled imaging agent for PET/CT detection of peritoneal carcinomatosis
–Phase 2Colorectal CancerJun 2029
Regadenoson
Adenosine A2a receptor agonist
ADORA2APhase 1Myocardial Ischemia; Heart Transplant Failure and Rejection; Sickle Cell DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT0548618218F Fluoroestradiol (ESTROTEP)Phase 4Metastatic Breast CancerOncologyApr 2025
NCT06639828Sonazoid™Phase 4Focal Liver LesionsOncologyJul 2026
NCT04604782RegadenosonPhase 1Myocardial IschemiaCardiovascularDec 2026
NCT03102125RegadenosonPhase 4Heart Transplant Failure and RejectionOtherJan 2027
NCT07873463GE-287Phase 2Cognitive DysfunctionNeurologyFeb 2027
NCT05583721RegadenosonPhase 2Sickle Cell DiseaseHematologySep 2027
NCT07472491Mangaciclanol (GEH200486 Injection)Phase 2Known or Highly Suspected Central Nervous System (CNS) LesionOtherNov 2027
NCT07219238GEH300079 (68Ga) InjectionPhase 2Colorectal CancerOncologyJun 2029

Targets

ESR1 (1) ADORA2A (1)

Companies with the same targets

AstraZeneca Pfizer Roche Eurofarma Laboratorios Eli Lilly Shanghai Best-Link Bioscience Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair Stemline Therapeutics Atossa Therapeutics Novartis

Companies built like this

Shanghai Best-Link Bioscience Shanghai Kechow Pharma Atossa Therapeutics Guangzhou Lupeng Pharmaceutical Company Stemline Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.